ReviewFrontiers in oncology2026
Role of lactylation modification in regulating lytic cell death.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Protein acylation and bone metabolism: bidirectional crosstalk linking metabolic reprogramming to skeletal homeostasis.Journal of molecular histology · 2026Review
- Roles of lactate and protein lactylation in neurogenesis and neurodegenerative disease.Journal of translational medicine · 2026Review
- Lactate-dependent regulation of ferroptosis: redox homeostasis, lactylation, and translational perspectives.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, lactate has been regarded primarily as the terminal product of glycolysis. However, recent research has elucidated its critical function as an epigenetic regulator via lactylation modification. Lactylation represents a novel post-translational modification (PTM) characterized by the covalent attachment of lactyl groups to lysine residues on both histone and non-histone proteins. This modification influences protein function at transcriptional and post-translational stages, thereby forging a direct connection between lactate metabolism and epigenetic regulation. Lytic cell death (LCD) encompasses a group of inflammatory programmed cell death modalities characterized by the rupture of the plasma membrane, playing a pivotal role in the pathogenesis of various diseases. This review provides a comprehensive synthesis of recent advancements in understanding the regulatory axis between L-lactate-induced lysine lactylation (KL-la) and LCD in disease contexts. Emerging evidence suggests that KL-la modulates several LCD subtypes, including pyroptosis, ferroptosis, and NETosis, thereby influencing disease progression and clinical outcomes. Notably, the regulatory effects of KL-la are highly context-dependent. Within the tumor microenvironment, KL-la primarily inhibits LCD, thereby promoting tumor cell survival. Conversely, in non-tumor conditions such as inflammation and ischemic injury, KL-la frequently enhances LCD, leading to increased tissue damage. This review also underscores therapeutic strategies that target lactate metabolism and KL-la-related enzymes to modulate LCD. Future interventions must incorporate the pathological context, cell-type specificity, and molecular targets. The advancement of context-responsive precision strategies, such as microenvironment-activated prodrugs or cell-specific delivery systems, will be crucial for the realization of safe and effective targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.